N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3,000 Diagnostic Accuracy of Electrocardiogram for Acute Coronary Occlusion Resulting in Myocardial Infarction
Myocardial Infarction · Acute Coronary Syndrome · Coronary Artery Disease
Primary: The Sensitivity and Specificity of ECG for Acute Coronary Occlusion. — 767; 282; 16 Participants
N/A N=1,392 Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)
Chest Pain · Acute Coronary Syndrome · Acute Myocardial Infarction
Primary: Rates of Major Cardiac Events (AMI or Cardiac Death) Within 30 Days — 0; 0; 0; 10 Participants
N/A N=1,748 Rapid Assessment of Potential Ischaemic Heart Disease With CTCA
Acute Coronary Syndrome
Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants
N/A N=130 Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes
Acute Coronary Syndrome (ACS)
Primary: Adherence to Refills and Medications Scale (ARMS) — 12.03; 12.18 units on a scale
Phase 4 N=100 Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
Acute Coronary Syndrome
Primary: Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™ — 98.4; 257.5 PRU…
Phase 2 N=8 Healthy Heart Habits
Acute Coronary Syndrome · Depression
Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale
Phase 2 N=94 Inflammation and Coronary Endothelial Function
Coronary Artery Disease
Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…
Phase 2 N=140 Polypill in Acute Coronary Syndrome
Acute Coronary Syndrome · Lipid Disorder · Coronary Artery Disease
Primary: Low Density Lipoprotein - Cholesterol — -6.74; 0.53 mg/dL — p=0.27
Phase 3 N=18,226 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke) — 439; 472 Participants — p=0.121
Phase 3 N=15,871 A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
Coronary Heart Disease
Primary: Incidence of Cardiovascular Mortality and Morbidity — 0.034050; 0.032759 Event per Patient Years of Followup
Phase 3 N=2,198 European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
Acute Coronary Syndrome
Primary: The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding — 5.1; 8.5 percentage of participants — p=0.0014
N/A N=900 Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64
Coronary Artery Disease
Primary: Number of Participants With Combination of All Cause Death, Non-fatal Myocardial Infarction (MI), and Hospitalization for Unstable Angina — 34; 28 Participants
N/A N=602 Early Risk Stratification in ED Chest Pain Patients
Acute Coronary Syndrome
Primary: Number of Patients With Major Adverse Cardiac Event — 42; 0; 437; 123 Participants
N/A N=871 Risk Markers in the Acute Coronary Syndromes
Chest Pain · Coronary Artery Disease · Unstable Angina Pectoris
Primary: Total Mortality. — 138 Participants.
N/A N=58 Disease Management for Coronary Artery Patients
Patient Empowerment · Coronary Artery Disease
Primary: Compliance Questionnaire Scores of the Participants — 22.25; 22.53 score on a scale
Phase 4 N=59 Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain
Chest Pain Syndrome
Primary: Length of Hospital Stay — 7.63; 8.20 Hours — p=0.79
N/A N=306 Data Acquisition for Optimization of Coronary Artery Disease (CAD) Algorithm
Coronary Artery Disease
Primary: The Area Under the Receiver Operating Characteristic Curve of the CAD-score to Separate CAD From Non-CAD Patients. — 73.4 percentage of 100
Phase 2 N=60 Evolocumab in Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Percent Change in LDL-Cholesterol — -68.78; -27.58 percent change
N/A N=251 PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis
Chest Pain · Cardiovascular Diseases · Angina Pectoris
Primary: Change in Clinicians' Treatment Decision After Age/Sex/Gene Expression Score — 38; 1; 1; 0 number of subjects — p=<0.001
Phase 2 N=510 Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Sensitivity, Specificity of Detecting Myocardial Ischemia (Reader 1) — 75.2; 67.7 % (n/N)
Phase 2 N=20 Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
Myocardial Ischemia
Primary: Quantification of Myocardial Blood Volume — 3.63; 1.23 seconds^-1
Phase 3 N=18,624 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke — 864; 1014 Participants
Phase 2 N=129 AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
Coronary Artery Disease
Primary: Change From Baseline in Creatinine-normalized u-LTE4 at Week 4 — 0.04; 0.09; 1.09 Ratio — p=<0.001
N/A N=169 Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes
Chronic Obstructive Pulmonary Disease · Acute Coronary Syndromes
Primary: COPD Diagnosis — 39 participants
Phase 4 N=100 The Effect of IV Cangrelor and Oral Ticagrelor Study
Acute Coronary Syndrome (ACS) · High On-treatment Platelet Reactivity (HTPR) · Microvascular Obstruction (MVO)
Primary: Degree of Platelet Inhibition Measured — 248.3; 145.2 Platelet Reactivity Units (PRU)
Phase 4 N=30 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina
Coronary Artery Disease
Primary: Change in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo — 8.8; 10.7 mL/min — p=0.756
N/A N=641 Acute Coronary Syndrome KCMC
Acute Coronary Syndrome
Primary: Acceptability as Measured by the Acceptability of Intervention Measure (AIM) — 4.82 score on a scale
N/A N=90 Management of Anger in Patients With Acute Myocardial Infarction (MAPAMI)
Myocardial Infarction
Primary: Difference in Flow-mediated Dilation in the Brachial Artery in the Base and After the Treatment. — 11.24; 7.70 percent change dilatation — p=0.05
N/A N=51 PCI Alternative Using Sustained Exercise
Cardiovascular Disease
Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio